Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial

We investigated clinical characteristics and outcomes of patients with significant valvular disease (SVD) in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial. ROCKET AF...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	European heart journal 2014-12, Vol.35 (47), p.3377-3385
Hauptverfasser:	Breithardt, Günter, Baumgartner, Helmut, Berkowitz, Scott D, Hellkamp, Anne S, Piccini, Jonathan P, Stevens, Susanna R, Lokhnygina, Yuliya, Patel, Manesh R, Halperin, Jonathan L, Singer, Daniel E, Hankey, Graeme J, Hacke, Werner, Becker, Richard C, Nessel, Christopher C, Mahaffey, Kenneth W, Fox, Keith A A, Califf, Robert M
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Anticoagulants - therapeutic use Aortic Valve Insufficiency - complications Aortic Valve Insufficiency - mortality Atrial Fibrillation - complications Atrial Fibrillation - drug therapy Atrial Fibrillation - mortality Clinical Research Factor Xa Inhibitors - therapeutic use Female Hemorrhage - chemically induced Humans Male Mitral Valve Insufficiency - complications Mitral Valve Insufficiency - mortality Morpholines - therapeutic use Rivaroxaban Stroke - etiology Stroke - mortality Stroke - prevention & control Thiophenes - therapeutic use Treatment Outcome Warfarin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!